Drug Use clinical trials at UCSF
2 research studies open to eligible people
N-Acetylcysteine for Smoking Cessation in Tobacco and Cannabis Co-Use
open to eligible people ages 18 years and up
Tobacco and cannabis co-use is a common and growing public health problem, especially in states that have legalized cannabis. There are no pharmacologic treatments for co-occurring tobacco and cannabis use. Co-use may make quitting either substance more difficult, given the synergistic effects of cannabis and nicotine on neurobiological systems that mediate reward and shared cues reinforcing co-use. N-acetylcysteine (NAC), an FDA-approved medication and over-the-counter supplement, has shown promise in animal studies and randomized controlled trials (RCTs) in reducing tobacco and cannabis craving and use.
San Francisco, California
Using Technology to Reduce Youth Substance Use
open to eligible people ages 13-18
The research project will focus on conducting a trial of whether a tailored SMS text-messaging intervention is efficacious in improving justice-involved youths' substance use or dual diagnosis treatment attendance and engagement.
San Francisco, California
Our lead scientists for Drug Use research studies include Marina Tolou-Shams, PhD Ellen Herbst, MD.
Last updated: